ArticleCancer research2026

Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity.

Linda Mårtensson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.